Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Dougherty

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
The Lancet. Oncology|June 3, 2014
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialJonathan Ledermann, Philipp Harter, Charlie Gourley, et al.
Nature Medicine|May 5, 2015
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790MKenneth S Thress, Cloud P Paweletz, Enriqueta Felip, et al.
Oncotarget|December 17, 2017
Comparative analysis of primary <i>versus</i> relapse/refractory DLBCL identifies shifts in mutation spectrumDanielle M Greenawalt, Winnie S Liang, Sakina Saif, et al.
The Lancet. Oncology|December 8, 2014
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trialAmit M Oza, David Cibula, Ana Oaknin Benzaquen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2023
Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker AssessmentMark Roschewski, Manish R Patel, Patrick M Reagan, et al.
Hematological Oncology|December 24, 2024
Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic LeukemiaElena Bibikova, Sara Parsa, Muskan Floren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2022
Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient StratificationRobert L Hollis, Alison M Meynert, Caroline O Michie, et al.
The Journal of Clinical Investigation|July 6, 2021
Distinct mechanisms govern populations of myeloid-derived suppressor cells in chronic viral infection and cancerEvgenii N Tcyganov, Shino Hanabuchi, Ayumi Hashimoto, et al.
Cancer Research|April 15, 2015
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical ModelsCatherine A Eberlein, Daniel Stetson, Aleksandra A Markovets, et al.
Plos Genetics|January 4, 2013
Genes contributing to pain sensitivity in the normal population: an exome sequencing studyFrances M K Williams, Serena Scollen, Dandan Cao, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
The Lancet. Oncology|June 3, 2014
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialJonathan Ledermann, Philipp Harter, Charlie Gourley, et al.
Nature Medicine|May 5, 2015
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790MKenneth S Thress, Cloud P Paweletz, Enriqueta Felip, et al.
Oncotarget|December 17, 2017
Comparative analysis of primary <i>versus</i> relapse/refractory DLBCL identifies shifts in mutation spectrumDanielle M Greenawalt, Winnie S Liang, Sakina Saif, et al.
The Lancet. Oncology|December 8, 2014
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trialAmit M Oza, David Cibula, Ana Oaknin Benzaquen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2023
Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker AssessmentMark Roschewski, Manish R Patel, Patrick M Reagan, et al.
Hematological Oncology|December 24, 2024
Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic LeukemiaElena Bibikova, Sara Parsa, Muskan Floren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2022
Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient StratificationRobert L Hollis, Alison M Meynert, Caroline O Michie, et al.
The Journal of Clinical Investigation|July 6, 2021
Distinct mechanisms govern populations of myeloid-derived suppressor cells in chronic viral infection and cancerEvgenii N Tcyganov, Shino Hanabuchi, Ayumi Hashimoto, et al.
Cancer Research|April 15, 2015
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical ModelsCatherine A Eberlein, Daniel Stetson, Aleksandra A Markovets, et al.
Plos Genetics|January 4, 2013
Genes contributing to pain sensitivity in the normal population: an exome sequencing studyFrances M K Williams, Serena Scollen, Dandan Cao, et al.
Pageof 4